These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26795874)

  • 21. Effect of augmenting cholinergic function on gait and balance.
    Mancini M; Fling BW; Gendreau A; Lapidus J; Horak FB; Chung K; Nutt JG
    BMC Neurol; 2015 Dec; 15():264. PubMed ID: 26697847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.
    Koshy Cherian A; Kucinski A; Wu R; de Jong IEM; Sarter M
    Psychopharmacology (Berl); 2019 Jun; 236(6):1701-1715. PubMed ID: 30607479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
    Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
    Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
    Li Z; Yu Z; Zhang J; Wang J; Sun C; Wang P; Zhang J
    Eur Neurol; 2015; 74(1-2):86-91. PubMed ID: 26288230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.
    Becker C; Lord SR; Studenski SA; Warden SJ; Fielding RA; Recknor CP; Hochberg MC; Ferrari SL; Blain H; Binder EF; Rolland Y; Poiraudeau S; Benson CT; Myers SL; Hu L; Ahmad QI; Pacuch KR; Gomez EV; Benichou O;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):948-57. PubMed ID: 26516121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylcholinesterase inhibitors and gait: a steadying hand?
    Moreau C; Devos D; Defebvre L
    Lancet Neurol; 2016 Mar; 15(3):232-3. PubMed ID: 26795875
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
    Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
    Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
    Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
    van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
    Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.